By 
Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough.
In a press release dated July 9th, the company said its UK subsidiary signed an “exclusive” multi-country commercial supply agreement with Fosun Diagnostics, a key division of Shanghai Fosun Pharmaceutical.
Despite the cosmic run today, Virax stock remains down some 10% year-to-date.
A sneak peek into the Fosun deal
Under the terms of the agreement, Virax will supply its ImmuneSelect product line across six major ASEAN markets: Thailand, Vietnam, Indonesia, Singapore, Malaysia, and the Philippines.
Note that the company’s ImmuneSelect includes specialized ELISpot assay plates used for cellular immune response profiling.
VRAX shares soared this morning primarily because, unlike typical biotech milestones that rely on multi-year clinical trial horizons, this deal sets up an immediate framework for product supply via direct purchase orders.
The commercial rollout is fast-tracked to start in Thailand, specifically targeting near-term client demand for tuberculosis-related research applications.
Adding to momentum on Thursday is algorithmic buying as Virax Biolabs ripped through its major moving averages (MAs), indicating shifting momentum in favour of the bulls.
Why are VRAX shares soaring aggressively today
Virax Biolabs is a micro-cap biotechnology company that brought in under $1 million in revenue over the past year.
Partnering with a powerhouse like “Fosun” instantly grants them access to an established regional commercial infrastructure and expansive customer network they couldn’t have built independently.
Investors should also note that VRAX stock has a tight float coming off a recent “1-for-25” reverse split – executed to regain compliance with Nasdaq’s minimum bid requirements.
When a fundamental, revenue-generating catalyst like this hits a low-float micro-cap stock, it often sparks a massive volume squeeze, which is exactly why trading volume blew past 57 million shares today compared to its usual 1-million daily average.
Should you chase the momentum in Virax stock?
Disciplined investors should still practice extreme caution before chasing Virax shares at these stretched levels.
Despite today’s fundamental catalyst, the biotech firm remains a super speculative microcap penny stock with a history of severe revenue constraints and net losses.
Because of its tight post-split float, VRAX is highly vulnerable to extreme volatility, algorithmic momentum traps, and pump-and-dump dynamics where early momentum buyers eventually dump shares on retail investors.
Moreover, micro-cap companies experiencing sudden volume surges often capitalize on the rally by launching dilutive secondary share offerings to raise capital as well. So dilution remains a near-term risk as well.
All in all, until this cross-border deal translates into sustained, multi-quarter sales growth on the balance sheet, chasing today’s vertical spike carries a high risk of severe capital impairment.
That said, the only Wall Street analyst that currently covers Virax Biolabs has a “Buy” rating on it, with the mean price target set at a rather bullish $25.
The post Why this biotech stock more than tripled on Thursday appeared first on Invezz